AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1061225 — intervention group
Group type: EXPERIMENTAL
Intervention: Isokinetic bench press at 2.0 sec speed
Number of subjects: 11
Study 1061225 — intervention group
Group type: EXPERIMENTAL
Intervention: Isokinetic bench press at 3.5 sec speed
Number of subjects: 11
Study 31516116 — intervention group
Group type: EXPERIMENTAL
Intervention: Malaria infection
Number of subjects: 445
Study 31516116 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent use of bed nets
Number of subjects: 445
Study 31516116 — intervention group
Group type: EXPERIMENTAL
Intervention: Not always using latrines and eating raw uncooked food
Number of subjects: 445
Study 31516116 — intervention group
Group type: EXPERIMENTAL
Intervention: Malaria and STH infections
Number of subjects: 445
Study 27059529 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin degludec/insulin aspart (IDegAsp)
Number of subjects: 178
Study 27059529 — intervention group
Group type: COMPARATOR
Intervention: Biphasic insulin aspart 30 (BIAsp 30)
Number of subjects: 178
Study 26608441 — intervention group
Group type: EXPERIMENTAL
Intervention: Improving sleep quality activities (4 sessions of 2 hours each)
Number of subjects: 59
Study 26608441 — intervention group
Group type: COMPARATOR
Intervention: Regular greeting calls (Control)
Number of subjects: 59
Study 23193010 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting metabolic rate (RMR)
Number of subjects: 41
Study 23193010 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in resting metabolic rate (RMR)
Number of subjects: 41
Study 21757372 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary PTA
Number of subjects: 58
Study 21757372 — intervention group
Group type: COMPARATOR
Intervention: SilverHawk atherectomy
Number of subjects: 58
Study 19422357 — intervention group
Group type: EXPERIMENTAL
Intervention: Acid+capsaicin (200 ml solution: 180 ml HCL 0.1 M and 2 mg capsaicin in 20 ml solvent)
Number of subjects: 15
Study 19422357 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 15
Study 17066105 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 G spinal needle
Number of subjects: 100
Study 17066105 — intervention group
Group type: COMPARATOR
Intervention: 26 G spinal needle
Number of subjects: 100
Study 15298635 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg
Number of subjects: 2645
Study 15298635 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg
Number of subjects: 2645
Study 15298635 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg
Number of subjects: 2645
Study 12577392 — intervention group
Group type: EXPERIMENTAL
Intervention: Shenmai injection (SMI) plus thrombolytic treatment
Number of subjects: 537
Study 12577392 — intervention group
Group type: COMPARATOR
Intervention: Thrombolytic treatment only (Control)
Number of subjects: 537
Study 9435936 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (CF) 500 mg orally twice daily
Number of subjects: 72
Study 9435936 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime (CT) 1 g intravenously twice daily
Number of subjects: 72
Study 29239627 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialectical Behavior Therapy (DBT)
Number of subjects: 106
Study 29239627 — intervention group
Group type: EXPERIMENTAL
Intervention: Object-Relational Psychotherapy (ORP)
Number of subjects: 106
Study 29239627 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 106
Study 27288987 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic-assisted laparoscopic surgery
Number of subjects: 101
Study 27288987 — intervention group
Group type: COMPARATOR
Intervention: Traditional laparoscopic surgery
Number of subjects: 101
Study 25037579 — intervention group
Group type: EXPERIMENTAL
Intervention: Responsive parenting intervention
Number of subjects: 316
Study 25037579 — intervention group
Group type: COMPARATOR
Intervention: Home safety control
Number of subjects: 316
Study 22699288 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 units/kg/day insulin glargine and glulisine
Number of subjects: 107
Study 22699288 — intervention group
Group type: COMPARATOR
Intervention: 0.25 units/kg/day insulin glargine and glulisine
Number of subjects: 107
Study 22699288 — intervention group
Group type: EXPERIMENTAL
Intervention: Both dosing groups (0.5 and 0.25 units/kg/day)
Number of subjects: 107
Study 19528133 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjudicated outcomes
Number of subjects: 95038
Study 19528133 — intervention group
Group type: COMPARATOR
Intervention: Reported outcomes
Number of subjects: 95038
Study 16255837 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical corticosteroids (clobetasol propionate 0.05%, betamethasone valerate 0.1%, clobetasone butyrate 0.05%)
Number of subjects: 19
Study 14733854 — intervention group
Group type: EXPERIMENTAL
Intervention: Consulting of internal medicine (CIM) in primary care
Number of subjects: 2167
Study 14733854 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 2167
Study 11552710 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental selenium
Number of subjects: 32400
Study 11552710 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental vitamin E
Number of subjects: 32400
Study 11552710 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32400
Study 9589312 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with eating disorders (specific types not detailed)
Number of subjects: 0
Study 9589312 — intervention group
Group type: COMPARATOR
Intervention: Non-patients
Number of subjects: 0
Study 8175215 — intervention group
Group type: EXPERIMENTAL
Intervention: Trefoil/Bifoil balloon catheter (n = 100, Group 1)
Number of subjects: 150
Study 8175215 — intervention group
Group type: COMPARATOR
Intervention: Inoue balloon catheter (n = 50, Group 2)
Number of subjects: 150
Study 8175215 — intervention group
Group type: COMPARATOR
Intervention: Inoue balloon technique
Number of subjects: 150
Study 3168936 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate (1 g QID before meals)
Number of subjects: 45
Study 3168936 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identical-looking)
Number of subjects: 45
Study 3168936 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate (for gastric variceal ulcers)
Number of subjects: 45
Study 3168936 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for gastric variceal ulcers)
Number of subjects: 45
Study 3168936 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulcer size influence
Number of subjects: 45
Study 31639790 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicorandil (10 mg, t.i.d., starting 2 days before and continuing for 2 days after the procedure)
Number of subjects: 252
Study 31639790 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicorandil
Number of subjects: 252
Study 31639790 — intervention group
Group type: COMPARATOR
Intervention: Control (standard hydration treatment only)
Number of subjects: 252
Study 25111433 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior therapy (behavior activation and problem-solving therapy)
Number of subjects: 80
Study 23399554 — intervention group
Group type: EXPERIMENTAL
Intervention: Elemental diet
Number of subjects: 127
Study 23399554 — intervention group
Group type: COMPARATOR
Intervention: Standard liquid diet
Number of subjects: 127
Study 21654719 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (tri-weekly for 6 weeks)
Number of subjects: 72
Study 21654719 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy
Number of subjects: 72
Study 21654719 — intervention group
Group type: COMPARATOR
Intervention: Sleep hygiene education (control group)
Number of subjects: 72
Study 18475154 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure (CPAP) treatment
Number of subjects: 33
Study 18475154 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 33
Study 17089507 — intervention group
Group type: EXPERIMENTAL
Intervention: SMA CPB circuits
Number of subjects: 28
Study 17089507 — intervention group
Group type: COMPARATOR
Intervention: Standard CPB circuits
Number of subjects: 28
Study 15689052 — intervention group
Group type: EXPERIMENTAL
Intervention: D‐003 (20 mg/day)
Number of subjects: 31
Study 15689052 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 11237927 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet plus exercise (DE)
Number of subjects: 40
Study 11237927 — intervention group
Group type: COMPARATOR
Intervention: Diet (D)
Number of subjects: 40
Study 9237088 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking with a distractor
Number of subjects: 124
Study 9237088 — intervention group
Group type: COMPARATOR
Intervention: Smoking without a distractor
Number of subjects: 124
Study 9237088 — intervention group
Group type: COMPARATOR
Intervention: Not smoking with a distractor
Number of subjects: 124
Study 9237088 — intervention group
Group type: COMPARATOR
Intervention: Not smoking without a distractor
Number of subjects: 124
Study 8481017 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen (2 to 4 mg per day)
Number of subjects: 52
Study 8481017 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 3115210 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (600 mg four times a day)
Number of subjects: 18
Study 3115210 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulindac (200 mg twice a day)
Number of subjects: 18
Study 3115210 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 29685459 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational leaflet intervention
Number of subjects: 400
Study 29685459 — intervention group
Group type: COMPARATOR
Intervention: Control group (no educational leaflet)
Number of subjects: 400
Study 28845007 — intervention group
Group type: EXPERIMENTAL
Intervention: Foley catheter for nephrostomy tube (research group)
Number of subjects: 137
Study 28845007 — intervention group
Group type: COMPARATOR
Intervention: Normal nephrostomy tube (control group)
Number of subjects: 137
Study 25181557 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron
Number of subjects: 69
Study 25181557 — intervention group
Group type: COMPARATOR
Intervention: Droperidol
Number of subjects: 69
Study 25181557 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 69
Study 23784369 — intervention group
Group type: EXPERIMENTAL
Intervention: Umeclidinium (10-350 μg)
Number of subjects: 56
Study 23784369 — intervention group
Group type: EXPERIMENTAL
Intervention: Umeclidinium (100 μg and above)
Number of subjects: 56
Study 23784369 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium bromide (18 μg)
Number of subjects: 56
Study 23784369 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 21757893 — intervention group
Group type: EXPERIMENTAL
Intervention: Marine omega-3 fatty acids (2,080 mg daily for 10 weeks)
Number of subjects: 34
Study 21757893 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 19452380 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole titrated-dose (starting dose 5 mg/day)
Number of subjects: 0
Study 19452380 — intervention group
Group type: COMPARATOR
Intervention: Aripiprazole fixed-dose (dose 15 mg/day)
Number of subjects: 0
Study 19452380 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole titrated-dose
Number of subjects: 0
Study 19452380 — intervention group
Group type: COMPARATOR
Intervention: Aripiprazole fixed-dose
Number of subjects: 0
Study 16422995 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram 20 mg i.v.
Number of subjects: 10
Study 16422995 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 15149875 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant stanol (STA)
Number of subjects: 5
Study 15149875 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant sterol (STE)
Number of subjects: 5
Study 15149875 — intervention group
Group type: COMPARATOR
Intervention: Intralipid
Number of subjects: 5
Study 11736751 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasmapheresis (10 days)
Number of subjects: 4
Study 11736751 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 4
Study 9459029 — intervention group
Group type: EXPERIMENTAL
Intervention: Computed lateral cephalometry (30% reduced radiation, 70 kV, 15 mA, 0.35 s)
Number of subjects: 20
Study 9459029 — intervention group
Group type: COMPARATOR
Intervention: Conventional lateral cephalometry (70 kV, 15 mA, 0.5 s)
Number of subjects: 20
Study 8204472 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin (5 mg/kg daily for 6 weeks)
Number of subjects: 46
Study 8204472 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 8204472 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin
Number of subjects: 46
Study 3284632 — intervention group
Group type: COMPARATOR
Intervention: Doxepin
Number of subjects: 0
Study 3284632 — intervention group
Group type: EXPERIMENTAL
Intervention: Marital therapy designed to enhance intimacy through self-disclosure
Number of subjects: 0
Study 3284632 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30797638 — intervention group
Group type: EXPERIMENTAL
Intervention: qHPV vaccine
Number of subjects: 1124
Study 30797638 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1124
Study 29184167 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol (NEB) 5/10 mg/day
Number of subjects: 60
Study 29184167 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (ATE) 25/50 mg/day
Number of subjects: 60
Study 29184167 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLAC)
Number of subjects: 60
Study 25403327 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapeseed/canola oil (RA) supplementation (50 g daily for 4 weeks)
Number of subjects: 0
Study 25403327 — intervention group
Group type: COMPARATOR
Intervention: Olive oil (OL) supplementation (50 g daily for 4 weeks)
Number of subjects: 0
Study 24779956 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic Training Group (ATG, n=19)
Number of subjects: 59
Study 24779956 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Aerobic and Resistance Training Group (CTG, n=20)
Number of subjects: 59
Study 24779956 — intervention group
Group type: COMPARATOR
Intervention: Control Group (n=20)
Number of subjects: 59
Study 22591446 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor physical therapy combined with neuromuscular electrical stimulation (NMES) on the tibialis anterior
Number of subjects: 0
Study 22591446 — intervention group
Group type: COMPARATOR
Intervention: Motor physical therapy alone
Number of subjects: 0
Study 18946808 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional foot orthoses (n=20)
Number of subjects: 40
Study 18946808 — intervention group
Group type: COMPARATOR
Intervention: Unshaped material (n=20)
Number of subjects: 40
Study 17559750 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release niacin (NIASPAN) 1 g (N1)
Number of subjects: 175
Study 17559750 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release niacin (NIASPAN) 2 g (N2)
Number of subjects: 175
Study 17559750 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 175
Study 15252223 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone maintenance therapy at a dosage of 80-100 mg per day
Number of subjects: 0
Study 15252223 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone maintenance therapy at a dosage lower than 40 mg per day
Number of subjects: 0
Study 15252223 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone maintenance therapy with treatment duration of 90 days or less
Number of subjects: 0
Study 15252223 — intervention group
Group type: EXPERIMENTAL
Intervention: Ancillary services provided at the beginning of methadone maintenance program
Number of subjects: 0
Study 15252223 — intervention group
Group type: EXPERIMENTAL
Intervention: Programs involving more participants
Number of subjects: 0
Study 12414201 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior-posterior electrode position
Number of subjects: 108
Study 12414201 — intervention group
Group type: COMPARATOR
Intervention: Anterior-lateral electrode position
Number of subjects: 108
Study 12414201 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross-over from anterior-lateral to anterior-posterior
Number of subjects: 108
Study 12414201 — intervention group
Group type: COMPARATOR
Intervention: Cross-over from anterior-posterior to anterior-lateral
Number of subjects: 108
Study 12414201 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall success after cross-over
Number of subjects: 108
Study 9649694 — intervention group
Group type: EXPERIMENTAL
Intervention: TCR Vbeta 2
Number of subjects: 7
Study 9649694 — intervention group
Group type: EXPERIMENTAL
Intervention: TCR Vbeta 2 and 17
Number of subjects: 7
Study 9649694 — intervention group
Group type: EXPERIMENTAL
Intervention: TCR Vbeta 2, 6, 18 and 19
Number of subjects: 7
Study 9649694 — intervention group
Group type: COMPARATOR
Intervention: TCR Vbeta 6, 13‐2 and 14
Number of subjects: 7
Study 8732136 — intervention group
Group type: EXPERIMENTAL
Intervention: Fetal blood transfusion, Chinese medicinal herbs, and Vitamin C
Number of subjects: 43
Study 8732136 — intervention group
Group type: COMPARATOR
Intervention: Western medicine alone
Number of subjects: 43
Study 2745320 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training (40 min at 50-70% VO2max for first 13 weeks, 75-85% VO2max for last 13 weeks)
Number of subjects: 47
Study 2745320 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (one set of 8-12 repetitions on 10 Nautilus machines, 3 sessions per week for 26 weeks)
Number of subjects: 47
Study 2745320 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 47
Study 886702 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive therapy for the 'intermediate' group (350 persons)
Number of subjects: 350
Study 886702 — intervention group
Group type: COMPARATOR
Intervention: Surveillance of 10% of the 'normal' group
Number of subjects: 350
Study 886702 — intervention group
Group type: COMPARATOR
Intervention: Surveillance of the whole 'pathological' group
Number of subjects: 350
Study 31451420 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated varicella zoster virus vaccine
Number of subjects: 0
Study 31451420 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 28771262 — intervention group
Group type: EXPERIMENTAL
Intervention: GF rice and corn pasta
Number of subjects: 13
Study 28771262 — intervention group
Group type: COMPARATOR
Intervention: Conventional wheat pasta
Number of subjects: 13
Study 26595853 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent bolus feeding (BOL)
Number of subjects: 246
Study 26595853 — intervention group
Group type: COMPARATOR
Intervention: Semicontinuous feeding (CON)
Number of subjects: 246
Study 23547959 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical year students
Number of subjects: 568
Study 23547959 — intervention group
Group type: EXPERIMENTAL
Intervention: Female students
Number of subjects: 568
Study 23547959 — intervention group
Group type: EXPERIMENTAL
Intervention: Neck region
Number of subjects: 568
Study 23547959 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower back region
Number of subjects: 568
Study 23547959 — intervention group
Group type: EXPERIMENTAL
Intervention: Students with minimum participation in ergonomics workshops
Number of subjects: 568
Study 23547959 — intervention group
Group type: EXPERIMENTAL
Intervention: Students unfamiliar with treatment and remedies for WMSD
Number of subjects: 568
Study 21467701 — intervention group
Group type: EXPERIMENTAL
Intervention: Efavirenz with fixed-dose lamivudine and abacavir
Number of subjects: 71
Study 21467701 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir-boosted atazanavir with fixed-dose lamivudine and abacavir
Number of subjects: 71
Study 21467701 — intervention group
Group type: COMPARATOR
Intervention: Both arms
Number of subjects: 71
Study 19628136 — intervention group
Group type: EXPERIMENTAL
Intervention: Project ALERT (school-based drug prevention program)
Number of subjects: 1901
Study 19628136 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1901
Study 16614789 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with Alzheimer's disease
Number of subjects: 0
Study 16614789 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 0
Study 15493522 — intervention group
Group type: EXPERIMENTAL
Intervention: ThermaCare HeatWrap
Number of subjects: 0
Study 15493522 — intervention group
Group type: COMPARATOR
Intervention: Johnson & Johnson Back Plaster
Number of subjects: 0
Study 15493522 — intervention group
Group type: COMPARATOR
Intervention: ABC Warme‐Pflaster
Number of subjects: 0
Study 11516867 — intervention group
Group type: EXPERIMENTAL
Intervention: LDR-ISRT (70 Gy/4-9 days)
Number of subjects: 51
Study 11516867 — intervention group
Group type: EXPERIMENTAL
Intervention: HDR-ISRT (60 Gy/10 fractions/1 week)
Number of subjects: 51
Study 9433587 — intervention group
Group type: EXPERIMENTAL
Intervention: Multipoint identity-by-descent method (MIM)
Number of subjects: 0
Study 9433587 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-region MIM with sets of six adjacent markers
Number of subjects: 0
Study 9433587 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-region MIM analysis
Number of subjects: 0
Study 8485791 — intervention group
Group type: EXPERIMENTAL
Intervention: Left lateral decubitus position (n = 22)
Number of subjects: 40
Study 8485791 — intervention group
Group type: COMPARATOR
Intervention: Sitting position (n = 18)
Number of subjects: 40
Study 3804564 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine/methylxanthine mixture (22 mg ephedrine, 30 mg caffeine, 50 mg theophylline)
Number of subjects: 0
Study 3804564 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine/methylxanthine mixture
Number of subjects: 0
Study 29570595 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster Training (CT) - 6 sets of 3 × 2 repetitions with 30 seconds rest every 2 repetitions and 4 minutes 30 seconds between sets
Number of subjects: 19
Study 29570595 — intervention group
Group type: COMPARATOR
Intervention: Traditional Training (TT) - 6 sets of 6 continuous repetitions with 5 minutes rest between sets
Number of subjects: 19
Study 27973936 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 20